Loading organizations...
Genome Insight, which recently rebranded to Inocras, is a San Diego, California-based precision medicine company that provides whole genome sequencing analysis and interpretation platforms for cancer and rare diseases. The organization operates a CLIA-certified and CAP-accredited laboratory to deliver clinically actionable genomic insights to healthcare providers through proprietary bioinformatics tools and diagnostic products like CancerVision and RareVision. The enterprise employs a specialized staff of approximately fifteen medical scientists and has secured roughly $48 million in total funding, which includes a $23 million Series B financing round completed in 2022. This institutional financial backing was provided by a syndicate of venture capital investors that includes recognizable firms such as Dunamu & Partners, InterVest, and Signite Partners. Genome Insight was originally founded in South Korea in 2020 by physician-scientists Young Seok Ju and Jeong Seok Lee.
Genome Insight has raised $23.0M across 1 funding round.
Genome Insight has raised $23.0M in total across 1 funding round.
Genome Insight has raised $23.0M across 1 funding round. Most recently, it raised $23.0M Series B in April 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 30, 2022 | $23M Series B | Dunamu & Partners | Asan Foundation, Samsung, SCL Group, UK, DSC Investment, Intervest, KC, Paratus Investment, Schmidt, Signite Partners, Vntg | Announced |
Genome Insight has raised $23.0M in total across 1 funding round.
Genome Insight's investors include Dunamu & Partners, Asan Foundation, Samsung, SCL Group, UK, DSC Investment, InterVest, KC, Paratus Investment, Schmidt, Signite Partners, VNTG.
